Video: Edie Falco and Cynthia Nixon Appear in New Stand Up To Cancer(TM) PSAs Designed to Educate Cancer Patients About the Importance Of Lowering One's Risk of Infection During Treatment
Posted on: Thursday, 10 September 2009, 08:00 CDT
LOS ANGELES, Sept. 10 /PRNewswire/ -- Award-winning actresses Edie Falco and Cynthia Nixon appear in a new Stand Up To Cancer(TM) (SU2C) public service campaign to educate cancer patients and their loved ones about the increased risk of infection during cancer treatment and the importance of learning how to manage one's risk.
To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/amgen/39907/
(Photo: http://www.newscom.com/cgi-bin/prnh/20090910/NY73333 )
Often patients are overwhelmed with medical information once they have been diagnosed with cancer. Many do not fully understand the risk of infection during chemotherapy and the potential impact it has on one's overall treatment success. The campaign's goal is to encourage cancer patients and their caregivers to actively work with their physicians to learn what can be done to lower the risk of infection before starting chemotherapy.
"Learning you have cancer comes as a complete shock and, at first, makes you feel powerless," says Falco, SU2C ambassador and cancer survivor. "You really need to take control early. It is important to work with your team of physicians at the outset to understand how to minimize your risk of infection and stay strong throughout your treatment plan."
"Being told that you have cancer is devastating," adds Nixon, SU2C ambassador and cancer survivor. "But you need to stay empowered. Through this Stand Up To Cancer campaign, we hope to encourage cancer patients and their loved ones to get all the facts, including how you can minimize the risk of infection during treatment."
The public service campaign, "Manage Your Treatment," includes both print and broadcast announcements, and was created by Stand Up to Cancer(TM) with support from Amgen. Starting this fall, the 30- and 60-second broadcast spots will begin airing and the print version of the PSA will appear in major women and lifestyle magazines. The PSA directs people to www.manageyourtreatment.com for more information.
Cancer patients are at higher risk for infection due to a compromised immune system caused by both the cancer itself and, often, by chemotherapy treatment. Neutropenia, a low white blood cell count, is a common and potentially dangerous side effect of chemotherapy. It can lead to a heightened risk of infection that can require hospitalization and be life-threatening. Each year, 60,000 cancer patients are hospitalized for chemotherapy-induced neutropenia. Neutropenia also can disrupt chemotherapy treatment, including both dose delays and dose reductions, which -- for certain types of cancer -- may impede a patient's ability to achieve the best long-term results.
ABOUT STAND UP TO CANCER(TM)
The Stand Up To Cancer initiative was created in 2008 to accelerate groundbreaking cancer research that will get new therapies to patients quickly and save lives. SU2C's goal is to bring together the best and the brightest in the cancer community, encouraging collaboration instead of competition. By galvanizing the entertainment industry, SU2C creates awareness and builds broad public support for this effort. Stand Up To Cancer is a program of the Entertainment Industry Foundation, the 501(c)(3) tax-exempt organization that serves as the collective philanthropy for the television and film businesses. Visit standup2cancer.org.
ABOUT AMGEN
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.
Amgen is a proud partner with Stand Up to Cancer(TM) as part of the company's ongoing commitment to advances in cancer treatment. Amgen believes this partnership not only provides additional needed funds for cancer research, but also demonstrates that joining forces is essential to fighting and overcoming this disease.
CONTACTS:
Ashleigh Koss: 805-313-6151 (Amgen)
Maurine Slutzky: 213-240-3923 (Stand Up To Cancer)
SOURCE SU2C/Amgen
Source: PR Newswire
Related Articles
- No Disparities by Race/Ethnicity in Risk of AIDS and Death Among HIV-Infected Patients in Kaiser Permanente's Integrated Delivery System, Research Study Finds
- CDC Foundation Partners with Amgen, CDC to Reduce Infections Among Cancer Patients
- Video: Afinitor(R) Approved in US as First Treatment for Patients With Advanced Kidney Cancer After Failure of Either Sunitinib or Sorafenib
- Nursing Research Grants Available to Improve Treatment of Patients With Auto-Immune Diseases and Cancer
- Aethlon Medical Reports Promising Treatment Results In Hepatitis-C Infected Patients
- More Than Half of Nurses Have Stopped or Delayed Patients' Chemotherapy Treatment, New Survey Shows
- A Drug's Ability To Achieve Sustained Viral Response in Genotype 1-Infected Patients Is the Most Important Driver of Prescribing Decisions for Hepatitis C Virus Treatment
- PLAVIX(R) (Clopidogrel Bisulfate) Recommended As Effective Cardiovascular Risk Reduction Treatment for Patients With Established Peripheral Arterial Disease (P.A.D.)
- Atherogenic Lipid Profile and Cardiovascular Risk Factors in HIV- Infected Patients (Ntar Study)
- Treatment of Hepatitis C in HIV/Hepatitis C Co-Infected Patients: What is the Evidence?
 |
 |
User Comments (0)
RSS Feeds